BeyondSpring (BYSI) investor relations material

Executive summary

• Focused on developing Plinabulin, a novel immune modulator for cancer, with ongoing and planned global Phase 3 studies targeting NSCLC and other indications.

• Plinabulin demonstrated enhanced efficacy and tolerability in ADC-based regimens, positioning it as a potential backbone agent for combination cancer therapies.

• SEED Therapeutics, a subsidiary using targeted protein degradation technology, advanced its lead asset into Phase 1 and entered collaborations with Eli Lilly and Eisai.

• The company reported disciplined execution across its portfolio, aiming for long-term value through clinical and strategic partnerships.

• No product sales revenue; operations funded by equity, loans, and collaboration payments.

Financial highlights

• Net loss from continuing operations was $2.2 million for Q1 2026, down from $2.6 million in Q1 2025.

• Consolidated net loss was $6.7 million for Q1 2026, compared to net income of $1.2 million in Q1 2025, which included a $7.0 million gain from the sale of SEED shares.

• Research and development expenses increased to $1.1 million for Q1 2026, mainly due to expanded drug manufacturing.

• General and administrative expenses decreased to $1.1 million, mainly due to lower incentive, share-based compensation, and personnel costs.

• Cash and cash equivalents plus short-term investments totaled $7.9 million as of March 31, 2026.

Outlook and guidance

• Expects continued significant expenses and operating losses as clinical programs advance.

• Additional funding will be required to support ongoing R&D, regulatory filings, and potential commercialization.

• Exploring strategic options including licensing, partnerships, asset sales, and financings.

• Forward-looking statements highlight risks related to financing, clinical trial outcomes, regulatory approvals, and market competition.

• The company aims to unlock long-term value through clinical progress and strategic partnerships.